Next Article in Journal
Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
Next Article in Special Issue
Emerging Role of Podocalyxin in the Progression of Mature B-Cell Non-Hodgkin Lymphoma
Previous Article in Journal
Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study
Previous Article in Special Issue
CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 12
Issue 2
10.3390/cancers12020328
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes

by
Ayumi Fujimoto
and
Ritsuro Suzuki
*
Department of Oncology and Hematology, Shimane University Hospital, Izumo 693-8501, Japan
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(2), 328; https://doi.org/10.3390/cancers12020328
Submission received: 4 December 2019 / Revised: 27 January 2020 / Accepted: 30 January 2020 / Published: 1 February 2020
(This article belongs to the Special Issue Recent Advances in the Pathogenesis of B Cell Malignancies)
Browse Figures
Review Reports Versions Notes

Abstract

Epstein-Barr virus (EBV) is a ubiquitous virus belonging to the human γ-herpes virus subfamily. After primary infection, EBV maintains a life-long latent infection. A major concern is that EBV can cause a diverse range of neoplasms and autoimmune diseases. In addition, patients undergoing hematopoietic stem cell transplantation or solid organ transplantation can experience post-transplant lymphoproliferative disorders (PTLDs) due to dysfunction or suppression of host’s immune system, or uncontrolled proliferation of EBV-infected cells. In recent years, the number of EBV-associated PTLD cases has increased. This review focuses on the current understandings of EBV-associated PTLD pathogenesis, as well as the risk factors and clinical outcomes for patients after allogeneic stem cell transplantation.
Keywords: post-transplant lymphoproliferative disorder; hematopoietic stem cell transplantation; pathogenesis; risk factors post-transplant lymphoproliferative disorder; hematopoietic stem cell transplantation; pathogenesis; risk factors

Share and Cite

MDPI and ACS Style

Fujimoto, A.; Suzuki, R. Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes. Cancers 2020, 12, 328. https://doi.org/10.3390/cancers12020328

AMA Style

Fujimoto A, Suzuki R. Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes. Cancers. 2020; 12(2):328. https://doi.org/10.3390/cancers12020328

Chicago/Turabian Style

Fujimoto, Ayumi, and Ritsuro Suzuki. 2020. "Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes" Cancers 12, no. 2: 328. https://doi.org/10.3390/cancers12020328

APA Style

Fujimoto, A., & Suzuki, R. (2020). Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes. Cancers, 12(2), 328. https://doi.org/10.3390/cancers12020328

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop